Summary
GLP-1 drugs, typically used for obesity, are showing promise in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder previously known as polycystic ovary syndrome, by improving symptoms like weight gain, insulin resistance, and hormonal balance.